Myasthenia gravis; cytotoxic potential of human sera in vitro and novel non-antibody, disease-modifying factors by Helgeland, Geir
1 
 
 
Myasthenia gravis; cytotoxic potential of human 
sera in vitro and novel non-antibody,  
disease-modifying factors 
Geir Helgeland 
 
 
 
Dissertation for the degree philosophiae doctor (PhD)  
at the University of Bergen 
 
2010  
2 
 
CONTENTS 
ACKNOWLEDGEMENTS .............................................................................................................. 4 
LIST OF PAPERS .......................................................................................................................... 6 
ABBREVIATIONS ......................................................................................................................... 7 
INTRODUCTION ........................................................................................................................ 10 
Myasthenia gravis ................................................................................................................ 10 
Epidemiology .................................................................................................................... 10 
Clinical features ................................................................................................................ 10 
Subgroups ......................................................................................................................... 11 
Pathophysiology ............................................................................................................... 14 
Diagnosis ........................................................................................................................... 17 
Treatment of MG .............................................................................................................. 20 
Myasthenic crisis .............................................................................................................. 26 
Myasthenia Gravis and the heart ..................................................................................... 27 
Heat Shock Proteins ............................................................................................................. 29 
Matrix Metalloproteinases ................................................................................................... 32 
Guillain-Barré syndrome ...................................................................................................... 35 
AIMS OF THE STUDY ................................................................................................................. 37 
MATERIALS AND METHODS ..................................................................................................... 38 
Patients and controls ........................................................................................................... 38 
Cell culture ........................................................................................................................... 38 
Cell viability assays (paper II) ............................................................................................... 38 
Antibody assays (papers III and IV) ...................................................................................... 39 
In vitro live cell calcium measurements ............................................................................... 40 
Statistical methods ............................................................................................................... 41 
SUMMARY OF RESULTS ............................................................................................................ 43 
3 
 
Morphological and cytotoxic effects of Myasthenia Gravis patient sera on human cells in 
culture (papers I and II) ........................................................................................................ 43 
Potential non-antibody disease mediating factors in MG (papers III and IV) ...................... 45 
In vitro live cell calcium measurements ............................................................................... 48 
GENERAL DISCUSSION.............................................................................................................. 50 
METHODOLOGICAL CONSIDERATIONS .................................................................................... 56 
Cell culture and choice of cell types (papers I and II) .......................................................... 56 
Serum samples from patients and controls (papers I-IV) .................................................... 58 
CONCLUSIONS .......................................................................................................................... 59 
ERRATA ..................................................................................................................................... 60 
REFERENCES ............................................................................................................................. 61 
 
 
 
  
 
 
 
 
 
 
 
  
4 
 
ACKNOWLEDGEMENTS  
This study was conducted at the University of Bergen, Norway in the years 2006-2009. 
Numerous people have contributed extensively with their knowledge and support. Any 
attempt to make a complete list of the names of the people who have helped me will fall 
short. 
The most significant person academically through these years has been Nils Erik Gilhus. His 
never ending enthusiasm, scientific insight and enormous capacity have made me pursue a 
PhD when other options seemed both easier and more tempting. Our meetings have always 
had room for discussing scientific as well as personal matters, for which I am grateful. You 
will remain an important role model for me, and hopefully we will continue to keep in touch 
even though I’m moving on to a different field of research. 
Geir Olve Skeie and Fredrik Romi have been helpful in sharing their knowledge whenever I 
came knocking on their office door. We agree on a lot, and disagree on some, but our 
discussions have always been to the point and helped me to expand my scientific field of 
vision. I truly appreciate your input.  
In the research lab, Hanne-Linda Nakkestad and Mette Haugen have been of great 
importance, always pointing me in the right direction when I’m looking for something or 
helping me with practical as well as scientific questions. The rest of the staff involved in 
different projects in the research lab deserves loads of credit.  
Steven Luckman did contribute significantly during the first years of my PhD-training. 
Various circumstances made you move back to the UK. I’m thankful for everything you 
taught me, and I hope you are well. 
My co-supervisor, Anne Kristine Jonassen, has been a great help in solving lab-oriented 
problems and in evaluation of cell viability assays. You and your research group included me 
from day one, and provided a kind and efficient working environment.   
Frank Helle Hansen has taught me real time live cell calcium measurement techniques while 
impressing me with his solution oriented approach to practical lab-work. Unfortunately all 
the hours spent in the darkness in the Faraday cage failed to produce publishable results.  
5 
 
Marianne Enger deserves thanks for sharing a fraction of her expertise in flow cytometry 
with me.  
Jone, Petter, Gyri, Bernd and Espen are both good friends and good colleagues. I feel 
privileged to have gotten to know you, and appreciate our extended lunches and afternoon 
cups of coffee in “Rotunden”. 
My parents Anne Beth and Svein have always supported me and provided motivation to 
keep me pursuing my goals. You have taught me the importance of education, and never 
allowed me to take lightly on my school work. More importantly you have provided a stable 
and healthy environment for growing up in. I wouldn’t have come this far without you.  
Off work, my brother, Øyvind, and my cousins, Erik and Espen, have been most important, 
spending countless hours skiing, working out or doing nothing at all.  
Finally, Inger Anne, who appeared in my life in the beginning of 2010, has made time off 
work even more enjoyable.  
 
  
6 
 
LIST OF PAPERS 
i. Luckman SP, Skeie GO, Helgeland G, Gilhus NE. Morphological effects of myasthenia 
gravis patient sera on human muscle cells. Muscle Nerve. 2006 Jan;33(1):93-103. 
ii. Helgeland G, Luckman SP, Romi FR, Jonassen AK, Gilhus NE. Myasthenia gravis sera 
have no effect on cardiomyocytes in vitro. J Neuroimmunol. 2008 Sep 15;201-
202:74-9.  
iii. Helgeland G, Petzold A, Hoff JM, Gilhus NE, Plant GT, Romi FR. Anti-Heat Shock 
Protein 70 antibody levels are increased in myasthenia gravis and Guillain-Barré 
syndrome (in press) 
iv. Helgeland G, Petzold A, Luckman SP, Gilhus NE, Plant GT, Romi FR. Matrix 
metalloproteinases in Myasthenia Gravis (submitted) 
  
7 
 
ABBREVIATIONS  
 
AChE-I Acetylcholine esterase inhibitor 
AChR Acetylcholine receptor 
AMC Arthrogryposis multiplex congenital  
AZT Azathioprine  
CD Cluster of differentiation 
CMAP Compound muscle action potential 
CsA Ciclosporin A  
CSF Cerebro spinal fluid 
CT Computer tomography 
Cy Cyclophosphamide  
DC Dendritic cells  
EAE Experimental autoimmune encephalitis 
EAMG Experimental autoimmune MG 
ECC Excitation-contraction coupling 
ECG Electrocardiogram 
ECM Extracellular matrix  
EDC  Extensor digitorum communis muscle 
EF Ejection fraction  
EOMG Early onset myasthenia gravis 
FDG-PET Fluordeoxyglucose-positron emission tomography 
GBS Guillain-Barré syndrome  
8 
 
GMG Generalized MG 
HLA Human leukocyte antigen 
HSP Heat shock proteins  
IFN Interferon 
IgG Immunoglobulin G 
IVIG Intravenous IgG  
LOMG Late onset myasthenia gravis 
LPS Lipopolysaccharide 
MC Myasthenic crisis 
MG Myasthenia gravis 
MGFA Myasthenia gravis foundation of America 
MHC Major histocompatibility complex 
MIR  Main immunogenic region 
MMF Mycophenolate mofetil  
MMP Matrix metalloproteinase 
MRI Magnetic resonance imaging 
MS Multiple sclerosis 
MuSK Muscle specific kinase 
MXT Methotrexate  
nAChR Nicotinic Acetylcholine receptor 
NMJ Neuromuscular junction 
OMG Ocular MG 
9 
 
PE Plasma exchange/plasmapheresis 
RA Rheumatoid arthritis  
RIA Radioimmune assay 
RNS Repetitive nerve stimulation 
ROI Regions of Interest 
RyR Ryanodine receptor 
SFEMG Single fiber electromyography  
SLE  Systemic lupus erythematosus  
SNMG Seronegative MG 
SR Sarcoplasmic reticulum 
SS Sjögren's Syndrome  
TIMP Tissue inhibitors of metalloproteinases  
WHO World Health Organization 
  
10 
 
INTRODUCTION 
Myasthenia gravis 
Epidemiology 
Myasthenia Gravis (MG) is a rare autoimmune disease. Reports from the past decades 
report an annual incidence between 4 and 11 per million [1-3], and prevalence ranging from 
70 to 150 per million [1-4]. Recent data from our department confirms these numbers, 
estimating the annual incidence to 7.2 per million, and prevalence 145 per million [5]. Both 
the prevalence and incidence rate have increased during the last 40 years [6], probably due 
to better diagnostics technology, improved medical treatment and epidemiological case 
finding, and a population consisting of more elderly individuals and less children.  
From generally being considered a disease affecting mainly young adults, it is now 
increasingly clear that the disease has a higher annual incidence and prevalence in the 
elderly, and is likely underdiagnosed in the very old [5, 7]. Difficulties in diagnosing this 
population may be due to age-related alteration of facial features, and because symptoms 
are believed to be caused by other neurological diseases, such as cerebrovascular disease or 
motor neuron disease [7-8]. MG onset also shows some sex-related characteristics. Among 
people below the age of 50, women are more likely to develop MG, whereas the sex ratio is 
near unity in the older population [5]. 
Clinical features 
The classical MG symptoms are weakness in striated muscle, muscular fatigue and reversible 
exercise-induced loss of muscle strength. Any groups of muscles can be affected, and the 
severity ranges from confinement to only one muscle group, e.g. ocular or periocular 
muscles, to generalized disease affecting proximal limb muscles and head and neck 
musculature. Approximately 2/3 of patients have ocular or extra-ocular muscle weakness as 
initial symptoms. While most patients progress to a more generalized disease, some 10% of 
patients retain this phenotype and are categorized as having ocular MG (OMG) [9]. 
Dysarthria, difficulties in swallowing and alteration of facial expression can be the 
dominating feature in some patients with affection of bulbar muscles. Reduced ventilatory 
capacity has been reported in MG patients with or without dyspnoea. Weakness in 
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respiratory muscles predispose to serious, and sometimes fatal, respiratory failure and 
respiratory infections. In a small group of patients, respiratory muscles can be affected to 
such a degree that mechanical ventilation is needed (myasthenic crisis).  
Subgroups 
Patients with MG can be divided into several subgroups, according to disease 
manifestations, age of onset and antibody profile. The following subgroups are commonly 
accepted: 
Ocular MG 
Patients are defined as having ocular MG (OMG) if their symptoms remain purely ocular, i.e. 
only affecting ocular and periocular muscles, for more than 2 years. Approximately 50% of 
patients which start off with ocular symptoms, develop generalized disease during this 
period. Some have suggested that in MG patients displaying only ocular symptoms at 
disease onset, having undetectable levels of acetylcholine receptor (AChR) antibodies (by 
conventional radioimmune assay (RIA)), and also steroid-treatment reduce the risk of 
developing generalized MG (GMG) [10-12], but these are retrospective studies without 
controls. Only half of OMG patients have detectable levels of anti-AChR antibodies [13], and 
anti-MuSK and anti-titin antibodies are not found. Thymus pathology is rarely seen.  
Early Onset MG (EOMG) 
Patients developing generalized MG without a thymoma before the age of 50 are said to 
have early onset MG. AChR-antibodies are present in about 80% [14], and thymus 
hyperplasia is often found. Antibodies towards titin are found in 10%, and antibodies giving 
a cross-striational binding pattern on tissue sections from skeletal or heart muscle are found 
in 25%. Antibodies towards ryanodine receptor (RyR) are very rarely detectable. Females are 
over represented in this group by a factor of 2-4. Thymectomy is believed to be effective 
[15-16].  
EOMG is strongly associated with HLA-B8*DR3 or ancestral haplotype 8.1 [17].  
Late Onset MG (LOMG) 
This group includes patients with onset of symptoms after the age of 50 years without a 
thymoma and not only ocular symptoms. Over 90% are anti-AChR positive, and antibodies 
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targeting other proteins (titin, RyR, IFN-α2 and IFN-ω) are commonly present. Male:female 
ratio is close to 1. Thymic pathology is seldom seen; hence thymectomy plays no major part 
in treatment [15, 18]. LOMG is associated with HLA-A3*B7*DR2  [19] and HLA-DR4 [20].  
Some patients with disease onset after 50 years show features similar to EOMG, and are 
denoted delayed early onset. They have an increased frequency of the extended HLA-A1-B8-
DR3 haplotype [21], thymic hyperplasia, and their treatment response is similar to the 
EOMG group [16]. 
Thymoma MG  
10-15% of MG patients have a thymoma, making their type of MG a true paraneoplastic 
disease. 30-40% of all thymoma patients develop MG. All thymoma MG patients have 
detectable levels of AChR antibodies and a high percentage have antibodies towards titin 
(90%) and RyR (75%) [15]. Onset of the disease peaks around the age of 50, but can occur at 
any point throughout life. There is no sex difference within the group. The patients differ 
clinically from those in the other MG groups in that they at time of onset more often have 
neck weakness and non-limb involvement [22]. No clear HLA-association has been found 
among thymoma MG patients.   
As with most other tumors, thymomas can be both benign and malign, and may show 
varying degrees of infiltration and invasion of surrounding tissues and structures. Surgery is 
the cornerstone in the treatment. Chemotherapy or radiation can be added for advanced 
stages of the disease, and gives a better prognosis for these patients [23-25].  
Anti-MuSK MG 
Antibodies towards the protein Muscle specific kinase can be detected in 5-40% of patients 
negative for anti-AChR antibodies. These patients almost never have antibodies towards 
AChR. The prevalence of anti-MuSK MG seems to be associated with geographical latitude, 
as only three patients are known in Norway (two ethnic Norwegians and one Pakistani 
woman), whereas reports from UK, Denmark, Poland and the Netherlands indicate a 15-20% 
prevalence, and in the Mediterranean region up to 40% [26]. MuSK-MG patients often have 
a more severe MG with prominent bulbar and upper body muscle involvement. There is a 
strong female preponderance, and muscle atrophy can be seen [27-28]. Although the anti-
MuSK subgroup show characteristic features, clinically it is impossible to distinguish this 
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subgroup from the other groups for the individual patient [16]. The response to 
acetylcholineesterase inhibitors (AChE-I) is reduced compared to the other MG groups [27]. 
MuSK antibody positive MG is strongly associated with HLA-DR14-DQ5 [29]. 
MG with low affinity antibodies to AChR 
In patients with generalized MG over 80% are positive for anti-AChR antibodies when using 
conventional radioimmune assays (RIA). Of the remaining 20%, 5-40% are positive for anti-
MuSK, whereas the rest were listed as seronegative. A report from Leite et al. showed the 
presence of low-affinity antibodies towards AChR when the protein is over-expressed and 
clustered in stable, non-muscle cell lines [30]. Over half of the patients previously listed as 
seronegative had these antibodies, which were capable of activating complement. These 
findings strongly indicate that a proportion of the patients previously categorized as 
seronegative, in fact have pathological antibodies. This is further supported by the 
observation that these patients are more similar to the anti-AChR patients than to the anti-
MuSK group, both regarding clinical features and response to treatment [30]. 
Seronegative MG (SNMG) 
The method utilized in [30] is quite labor intensive compared to the standard method for 
measuring anti-AChR antibodies. It requires co-transfection of several genes into a 
eukaryotic cell of human origin, and a manual evaluation of the test by means of 
immunofluorescence. This makes it difficult to standardize, and the conventional anti-AChR 
RIA remains the method of choice. As a result the MG group denoted seronegative MG has 
to be viewed as a heterogeneous group consisting of both anti-AChR positive and –negative 
patients. This heterogeneity makes it difficult to interpret studies which use the presence of 
anti-AChR antibodies as a grouping variable.  
This group comprises only 10-20%, of MG patients, and has decreased in size due to the 
discovery of low affinity anti-AChR antibodies [30]. These patients have in their sera no 
detectable antibodies against AChR and MuSK. Improvement with plasmapheresis, reduced 
number of AChRs on the muscle endplate and the observation that immunoglobulin from 
patients can transfer the disease to animals support SNMG as an antibody-mediated 
disease. Non-antibody factors may also play a role. The lack of detectable antibodies makes 
the diagnostic process more challenging as neither electrophysiological examinations nor 
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response to edrophonium have the same sensitivity and specificity as the anti-AChR assay. 
The patients are clinically heterogeneous. There seem to be subtle clinical differences 
between seropositive and seronegative MG, but these are difficult to quantify [31]. 
Pathophysiology 
The developmental process of the neuromuscular junction (NMJ) is not known in great 
detail. Agrin, a proteoglycan secreted from the nerve terminals, play a crucial role in 
clustering of the nicotinic AChRs (nAChR). Anchoring of these clusters on the muscle 
membrane is reached through agrin/MuSK interaction and expression of the protein rapsyn 
(receptor associated protein of the synapse), but the biochemical specifics concerning this 
process remain unclear [32].   
AChRs are part of a superfamily of pentameric neurotransmitter-gated ion channels. Each 
channel consists of five homologous subunits organized around a central ion channel. cDNA 
from 16 receptor subunits have been cloned from several species: nine α-subunits, four β-
subunits and one δ-, γ- and ε-subunit [33]. 
There are two types of muscle nAChRs, the fetal and the adult form. The fetal type, with the 
composition (α1)2βγδ, is expressed during embryogenesis and is replaced by the adult 
isoform after innervation. However some muscles, notably the extraocular muscles, still 
express fetal AChR [9]. Adult nAChR differs from fetal nAChR in that a ε-subunit replaces the 
γ-subunit. Although the mechanism for this γ/ε-subunit shift is not known in detail, it is clear 
that ACh-mediated muscle activity stimulates the shift, and that both subunits are essential 
for normal muscle development and innervation [32].  
In most cases, MG is caused by autoantibodies binding to the nAChR on the post-synaptic 
membrane in the neuromuscular synapse. More than half of the autoantibodies are 
directed towards a conformation-dependent region called the main immunogenic region 
(MIR) on the α1-subunit. Binding to this region allows for the cross linking of two adjacent 
AChRs  [33].  
Anti-AChR antibodies found in MG can bind to both fetal and adult form of nAChRs. 
Antibodies targeting the γ-subunit will not give symptoms in adults, but can cause 
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congenital malformations and muscle weakness, characteristic of arthrogryposis multiplex 
congenita, in children of antibody-positive mothers [33]. 
Commonly, three antibody-mediated pathophysiological mechanisms are recognized in anti-
AChR positive MG [9]: 
1. Antibodies bind to the AChRs in the NMJ and activate the complement system. This 
leads to localized membrane destruction, ultimately causing an altered NMJ-
morphology with reduced height of the post-synaptic membrane folds and a 
widened synaptic cleft. 
2. AChRs are cross-linked and endocytosed and degraded by the muscle cell, a process 
known as antigenic modulation. This increased receptor turnover leads to decreased 
amount of receptors on the cell surface. 
3. The anti-AChR antibodies block the agonist binding site, preventing ACh-mediated 
depolarization of the post-synaptic membrane. 
Patients with anti-MuSK almost never have antibodies towards AChR in their sera, and their 
disease is considered to be an immunologically separate form of MG. In animal studies, anti-
MuSK inhibits agrin-mediated AChR-clustering in vitro and reduces postsynaptic AChR levels 
in vivo [34]. The antibodies also have an inhibiting effect on regenerating end-plates [35].  
Apart from anti-AChR and anti-MuSK antibodies, a variety of other antibodies targeting 
different muscle proteins have been detected in MG-patients [36-39]. RyR is an ion channel 
in the sarcoplasmic reticulum (SR) of skeletal muscle cells, and releases calcium into the 
cytosolic space upon sarcolemma depolarization and activation of the dihydropyrimidine 
receptor [40]. MG-associated anti-RyR antibodies are capable of inhibiting RyR-function in 
vitro, when the protein is directly exposed to antibodies [41], but their ability to block 
function in live cells or in vivo have not been shown. MG patients also have prolonged 
excitation-contraction coupling (ECC) time [42]. In vitro studies on MG muscle biopsies show 
non-AChR mediated changes in ECC [43]. These findings indicate that mechanisms beside 
AChR-defects play a role in disease pathogenesis. 
Disease severity correlates with antibody levels towards titin. Titin is a huge filamentous 
protein, third most abundant in muscle, and functions both as a scaffold for the sarcomere 
16 
 
unit and as a spring to give skeletal muscle its biomechanical properties during contraction 
and relaxation [44]. 
The occurrence of anti-RyR and anti-titin antibodies is most frequent in patients with late 
onset or thymoma MG. Both antibodies are associated with disease severity [45], but no 
direct evidence has been demonstrated for their role in MG pathogenesis. Both proteins are 
intracellular proteins, and should therefore be “unreachable” for circulating antibodies, 
though antibody internalization has been described [46]. 
The association between MG and thymus and thymoma has been known for a century. The 
thymus has a crucial role in development of the immune system, as congenital absence of 
the thymus causes life-threatening immunodeficiency [47]. The thymus is central in T-cell 
development. CD4-CD8- cells, which are believed to be primitive T-cell precursors [48-49], 
mature into CD4+CD8+ cells before attempting to rearrange their T-cell receptor genes. If 
successful, the cell proceeds to two stages of selection, where the cells ability to recognize 
self-MHC molecules (positive selection, which takes place in the cortex), and not recognize 
self-proteins (negative selection, which takes place in the medulla) is tested, before the cell 
is released from the thymus into the circulation [47, 50]. 
According to WHO’s classification, thymomas are divided into group A, group B and the 
mixed AB group. Type A has a medullary appearance, whereas type B exhibits features of 
the thymic cortex, indicating that the tumor originates from the cortical epithelium of the 
thymus [51]. The observation that MG is more frequently associated with B-type tumors 
indicates that thymic structure is important in the pathogenesis of thymoma MG [50]. 
Furthermore, MG is associated with a high CD4+CD8+ count [50], a cell type commonly found 
in type B thymomas [51]. The generation of self-reactive T-cells may thus be explained by 
the lack of a functional antigen-presenting medullar structure with loss of intrathymic 
negative selection as a consequence.  
Another theory with less emphasis on thymic structure explains T-cell selection through T 
cell receptor (TCR) -avidity and -affinity, in which the positive and negative selection relies 
on both the number of TCRs binding to its antigen-MHC-II counterpart (avidity) and the 
strength of the binding (affinity). According to this model, no or weak TCR binding will not 
provide the cell with sufficient signals to survive, whereas too strong binding (above an 
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undefined threshold) to self-peptide-MHC-II will trigger apoptosis. The expression of HLA-DR 
in type B thymomas is lower than in the normal thymus, and could theoretically cause a T-
cell selection-shift allowing self-reactive T-cells into the circulation [50]. 
B-cells don’t have the same level of quality control as T-cells. B-cell activation, by most 
protein antigens, and subsequent antibody production, requires an additional stimulus from 
helper T-cells (TH). Failure to produce this second stimulus causes the B-cell to die, a process 
known as clonal deletion [47]. MG patients have CD4+ TH-cells in their circulation, and 
patients experience improvement after treatment with anti-CD4 antibodies. The role of 
CD4+ TH-cells has been demonstrated in experimental systems where CD4 deficient mice 
failed to develop experimental autoimmune MG (EAMG). It has also been shown that CD4+ 
TH-cells specific for AChR-epitopes can induce anti-AChR antibody production and MG-
symptoms [9]. 
Diagnosis  
Patient history 
MG patients typically present with weakness in voluntary muscles which worsen through 
the day and during exercise. Symptoms from ocular or extraocular muscles, such as diplopia 
and ptosis are common, but symptoms can arise from bulbar muscles with dysphagia, 
dysphonia or dysarthria, or present with respiratory difficulties. The bulbar symptoms can 
easily be misdiagnosed as other neurological diseases, e.g. cerebrovascular disease, 
especially in the elderly. Differential diagnoses include upper motor neuron disease, stroke, 
polymyositis, multiple sclerosis and unspecific fatigue. 
Clinical examination, MGFA-score 
The main objective when examining the patient suspected to have MG is to confirm the 
patient’s sensation of fatigue and muscle weakness as objectively detectable and 
reproducible, representing the type of paresis found in MG patients. The examiner should 
perform a ptosis-test, in which the patient is to gaze upwards for more than 30 seconds 
while the examiner notes any signs of ptosis or gaze deviation. Symptoms from proximal 
limb muscles can be tested when the patient extends an arm or a leg, and tries to maintain 
the position of the limb for a period of time. Dysphonia and dysarthria, if present, will often 
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reveal itself while taking the patient’s medical history. Potential respiratory involvement 
should be thoroughly sought for.  
After having concluded upon the MG diagnosis, the patient’s symptoms should be graded 
according to the Myasthenia Gravis Foundation of America (MGFA) classification scale [52]. 
Pharmacology 
The pharmacological assessment of MG relies on the rapid increase in muscle strength after 
intravenous administration of the acetylcholine esterase inhibitor edrophonium (Tensilon). 
Effects of the drug occur within seconds to minutes and wear off after about an hour. The 
patients usually report symptom relief, but the observer should be able to objectively 
observe an improvement to confirm the test as positive for MG. The test is important in the 
assessment of MG, with sensitivity and specificity rates of 0.92 and 0.97, respectively, for 
OMG and 0.88 and 0.97 for GMG [53]. An alternative pharmacological approach to the 
diagnosis of MG is initiating per oral treatment of a patient suspected of having MG with 
pyridostigmine, and to assess the symptoms after a few days. 
Antibody-testing 
Around 85% of MG patients have antibodies towards AChR, and the MG diagnosis 
traditionally rests quite heavily on the results from testing for these antibodies. The 
antibody assay most often used is a radioimmune assay (RIA) using AChRs labeled with 125I-
alpha-bungarotoxin, where immune complexes are precipitated by secondary anti-human 
IgGs [54]. 
Several studies, of varying quality, have examined the sensitivity and specificity of such 
tests, and have been reviewed by Benatar [53]. Generally, the sensitivity estimates in the 
higher quality studies are lower than in the studies of poor quality. The specificity is equally 
high (0.97-0.99) in all studies, irrespective of study design or whether the patients had OMG 
or GMG. For OMG, the pooled estimate of sensitivity ranged from 0.44 to 0.66, and in GMG 
from 0.90 to 0.96. This clearly shows that both a positive and a negative test is useful in 
assessment of potential MG, but also that a positive test is more helpful than a negative one 
when OMG is suspected [53]. All patients with a negative test for anti-AChR and still 
suspicion of MG should be tested for anti-MuSK antibodies.  
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Reports on low-affinity anti-AChR antibodies in MG patients previously thought to be 
seronegative have been published [30], but the method for this test has not yet been 
standardized, and is not a part of routine diagnostic work-up.  
Antibodies against titin are found in 95% of thymoma MG patients, but only have a 
specificity of 39% for a MG patient having a thymoma. Anti-RyR antibodies are detected in 
14% of MG sera, but are only found in the late onset and thymoma MG groups [15]. 
Together, this makes the detection of these auto-antibodies a valid supplementary tool to 
image diagnostics in deciding whether the patients should be thymectomized or not. The 
production of titin antibodies is not dependent on the pathogenic actions of anti-AChR 
antibodies, as they do not appear in sera from patients with long-standing, early onset MG 
and thymus hyperplasia [21]. RyR antibodies are in some MG patients able to inhibit calcium 
release from isolated terminal cisternae fractions [41], but a direct role in pathogenesis is 
yet to be discovered. Both titin and RyR antigens are intracellular, and no studies have 
shown that antibodies can bind to these proteins in vivo. 
Neurophysiology 
Neurophysiological tests in the assessment of MG include repetitive nerve stimulation (RNS) 
and single fiber electromyography (SFEMG). RNS at 2-5 Hz shows a decremental response in 
MG patients. This is due to depletion of the immediate ACh stores at the NMJ and a 
reduction of the safety factor, thereby a reduced probability of neuromuscular transmission. 
The test is considered positive when the fourth compound muscle action potential (CMAP) 
decreases more than 10%. The sensitivity and specificity of the test depends on which 
muscles are tested, the technique of the operator and whether the patient uses AChE-Is 
[55]. SFEMG is considered the most sensitive diagnostic test for detecting abnormal muscle 
transmission. It is time consuming and technically demanding. The method is based on 
simultaneous recording of muscle fiber action potentials from two adjacent muscle fibers. 
The difference in time between the firing of one muscle fiber action potential compared to 
the other is termed neuromuscular jitter. Preferably, an affected muscle should be tested. In 
many centers, musculus extensor digitorum communis (EDC) is initially examined, thereafter 
proceeding to a facial muscle if the results from EDC are normal [55]. SFEMG has a lower 
sensitivity and specificity in OMG than in GMG. A systematic review of electrophysiological 
methods in MG diagnostic work up concluded with a sensitivity of 75% to 98%, and 
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specificity ranging from 96% to 98% for GMG. For OMG the numbers were 62% to 97% and 
73% to 96%, respectively [53]. 
Imaging 
Patients that are diagnosed with MG or are suspected of having the disease should undergo 
radiological examination of the anterior chest cavity to look for abnormalities of the thymus. 
In MG, differentiating thymic hyperplasia and thymoma from the normal thymus is of main 
importance. Small anterior intramediastinal masses that do not distort the mediastinal 
contours will not be detectable by chest radiography [56].  
Contrast enhanced CT imaging is considered equal or superior to MRI for the assessment of 
thymic masses, except in the cases of thymic cysts. MRI can give additional information 
when locally advanced disease with infiltration of surrounding organs is suspected and CT 
gives equivocal information [56-57]. FDG-PET can be used to distinguish between different 
types of thymic masses and to evaluate the presence of metastatic disease [58]. MRI with 
chemical shift uptake can be useful in deciding whether the patient has a hyperplastic 
thymus or thymoma, but its ability to discriminate pathological and healthy thymi remains 
unclear.[59] 
Treatment of MG 
Pharmacological 
Drug treatment of MG should take into account the extent of symptoms the patient is 
experiencing as well as progression or remission of symptoms. Initial treatment for all MG 
subgroups is acetylcholine esterase inhibitors (AChE-I), of which pyridostigmine is the most 
widely used. This inhibits the breakdown of ACh in the NMJ, leading to increased levels of 
ACh, and increased chances of receptor binding and postsynaptic depolarization. AChE-I 
treatment is only symptomatic, and is most helpful when used in newly diagnosed MG and 
as long term treatment of mild disease [60]. Adverse effects include gut hypermobility, 
hyperhidrosis, excessive respiratory and gastrointestinal secretions and bradycarida, and are 
caused by the increment of ACh both in nicotinic and muscarinic synapses. Optimal dosage 
is determined by the balance between improvement in muscle strength and degree of 
adverse effects [60].  
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Corticosteroids 
In many MG patients, treatment with AChE-I alone is not sufficient, and coadministration of 
immunosuppressants is necessary. Oral prednisolone is considered a first-line 
immunosuppressive treatment [60]. Recommended starting dose is 10-25mg on alternate 
days, and with a gradual of increase the dose to 60-80mg on alternate days. Remission 
usually occurs within 4-16 weeks. The prednisolone dose should subsequently be reduced 
slowly to the minimum effective dose given every other day. If the starting dose is too high, 
some patients experience a worsening of symptoms after 4-10 days, and the treatment may 
precipitate a MG crisis [60].  
Short term methylprednisolone pulse treatment versus placebo has been reported safe and 
efficient [61], but the study is small and limited to patients with moderate MG. A Cochrane 
review of the treatment of MG with corticosteroids concluded that corticosteroids offer 
significant short term benefit, and are not inferior to azathioprine or intravenous IgG (IVIG) 
[62]. 
Prednisolone, and corticosteroids in general, have a variety of side effects which limit their 
long term use. Adverse effects include obesity, development of Cushingoid features, 
hypertension, reduced glucose tolerance, diabetes mellitus, increased susceptibility to 
infections, osteoporosis, myopathy, peptic ulcer disease, anxiety and psychoses.  
Azathioprine 
Azathioprine (AZT) is a pro-drug which is converted to 6-mercaptopurine. It interferes with 
the purine metabolism acting as a purine antagonist, and inhibits DNA and RNA synthesis. 
This causes a blockade of T- and B-cell proliferation. Azathioprine is recommended to be the 
first choice immunosuppressant drug when treating MG patients. Therapeutic response may 
be delayed for as long as 12 months and maximal effect may not be seen until after 24 
months. Hence a combination of azathioprine and prednisolone is often initiated before a 
gradual tapering of prednisolone when clinical improvement is observed [60]. A small 
randomized controlled trial (RCT) with 34 MG patients concluded that azathioprine used 
together with prednisolone reduces the maintenance dose of prednisolone, gives longer 
remissions and fewer side effects than when using prednisolone alone [63]. Non-
randomized evidence suggests that azathioprine alone has an effect in treatment of MG 
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[64]. Adverse effects include bone marrow deficiency and hepatotoxicity, and calls for 
careful monitoring of full blood cell count and liver enzymes. Less severe side effects, such 
as gastrointestinal disturbances and flu-like symptoms are seen in 10%, and usually occur 
within the first few days of treatment [65].  
Methotrexate 
Methotrexate (MXT) is a folate antagonist preventing synthesis of tetrahydrofolate, which is 
used in the conversion of dUMP to dTMP needed in DNA synthesis. Other mechanisms of 
action have also been suggested [66]. Consensus guidelines recommend using MTX in 
patients not responding to AZT. The drug is thoroughly studied in other autoimmune 
diseases, but evidence with sufficient quality lacks for MG [65]. 
Cyclophosphamide 
Cyclophosphamide (Cy) has mainly a B-cell effect and suppresses antibody production. 
Effects on T-cells can also be achieved, but this is dependent on timing of administration 
and dosage [66]. It is an alkylating agent with mutagenic properties and a relatively high risk 
of toxicity, and may cause bone marrow depression, kidney damage, increases the risk of 
infections and development of neoplasms. Evidence supporting its effectiveness in MG 
treatment or steroid sparing is scarce [64]. Due to its adverse effects, usage is limited to 
patients intolerant or unresponsive to AZT, MTX, ciclosporin A or mycophenolate mofetil 
[64-65]. 
Ciclosporin A 
Ciclosporin A (CsA) forms complexes with cyclophilin which through a series of steps inhibit 
translocation of transcription factors involved in synthesis of IL-2, IL-4 and CD40L to the 
nucleus. The drug also acts on the JNK- and p38 signaling pathways triggered by antigen 
recognition in T-cells [66]. Randomized and non-randomized evidence demonstrates its 
effect in MG treatment, both used alone [67] or in combination with steroids [68-70]. Like 
Cy, CsA has serious side effects, including systemic hypertension and nephrotixicity, and 
should only be considered in patients intolerant or unresponsive to AZT.    
Mycophenolate mofetil  
Mycophenolate mofetil (MMF) has an immunosuppressive effect through its active 
metabolite mycophenolate acid by inhibiting inosine 5’-monophosphate dehydrogenase 
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which is the rate limiting enzyme in guanine nucleotide synthesis. Non-randomized studies 
on the use of MMF in MG have indicated both improvement of symptoms and a steroid 
sparing effect. [71-73] Randomized trials, however, have not demonstrated the same effect, 
possible because of a slow onset of action.[64, 74] MMF has a low frequency of adverse 
effects compared to Cy and CsA, and those observed are usually mild, including nausea, 
headache and diarrhea.[73]   
FK506 (Tacrolimus) 
FK506 is phosphorylated in cells to act as an inhibitor of inosine monophosphate 
dehydrogenase. Reversal of lymphocyte proliferation suppression by guanine suggests this is 
the primary mechanism of action [66]. Furthermore, it acts on the calcium-calcineurin 
pathway to inhibit T-cell proliferation, and potentiates ECC in skeletal muscle through 
modulating calcium release through RyR [60, 75]. Case-reports attribute a rapid onset of 
effect to the RyR-modulating properties of the drug [76]. A randomized, unblinded study 
demonstrated that FK506 is effective, well tolerated and reduces the need for other 
immunotherapy [77]. FK506 should be tried in MG patients with poorly controlled disease, 
in particular perhaps patients positive for anti-RyR antibodies[65]. 
Antibodies towards leukocyte antigens 
Treating autoimmune diseases with monoclonal antibodies targeting CD20 and CD4 is a 
relatively new treatment option. Anti-CD20 antibodies were originally designed for use in 
patients with lymphoma, but effects have been demonstrated in rheumatoid arthritis (RA), 
systemic lupus erythematosus and multiple sclerosis (MS). It causes a rapid depletion of 
CD20+ B-lymphocytes, probably through antibody dependent cell-mediated cytotoxicity 
[78]. CD4 is a part of the T-cell receptor complex which recognizes peptides presented by 
MHC class II molecules. Presentation of an antigen to a CD4+ T-cell activates both the T-cell 
and the antigen presenting cell. Antibodies targeting CD4 inhibits this mode of activation, 
resulting in decreased immune activation [79]. Case-reports from successful treatment of 
MG patients with monoclonal antibodies towards B-cells (anti-CD20) [80-81] and T-cells 
(anti-CD4) [82] have been published. Although both reporting good outcome, more 
thorough research is needed before any recommendations can be given [65].  
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Plasma exchange and intravenous immunoglobulin G 
Plasma exchange (PE) and intravenous immunoglobulin G (IVIG) share indications for use: 
rapidly progressing disease, preparation of patients for surgery and as an adjuvant to reduce 
the adverse effects of oral immunosuppressants. In plasma exchange antibodies are 
removed from sera by membrane filtration or centrifugation. Patients experience 
improvement after 2-7 days, and the effect lasts for up to 3 months [65]. Short term benefit 
from PE has been reported in several case series, but no adequate RCTs have been 
performed. IVIG works by interfering with an array of different immunoregulatory 
components, including costimulatory molecules, adhesion molecules, cytokines, antibodies 
and the complement system [83]. IVIG gives a better response than placebo in severe MG 
exacerbation. Any benefits of IVIG compared to PE have been addressed in a Cochrane 
review which concludes that of two performed RCTs, one significantly demonstrated the 
superiority of IVIG to PE, whereas the other did not [84]. Long term therapy with PE or IVIG 
for stable MG is not recommended [65]. 
Non-pharmacological treatment options 
Weight control, training and other life style modifications are considered important, but 
there is no solid evidence to support the recommendation [16, 65]. Some improvement in 
muscle strength can be achieved through physical exercise [85], and respiratory training is 
also beneficial [86]. 
Pregnancy in MG is usually uncomplicated; however MG patients have an increased risk of 
delivery complications and intervention during birth. No difference in severe birth defects is 
observed between MG and healthy women [87]. Anti-AChR antibodies transplacentally 
acquired by the fetus can cause transient neonatal myasthenia and require close follow up 
and even AChE-Is, depending on the severity of the disease [16]. It occurs in 10-15% of MG 
births [88]. All women with MG should give birth at units with access to ventilatory 
supportive treatment for the newborn. Arthrogryposis multiplex congenital (AMC) is a 
severe and often fatal birth defect that can be caused by anti-AChR [88]. It is characterized 
by hypotonia, multiple joint contractures, ptosis and respiratory distress [89], and is noted 
to occur in 2.2% of MG births in Norway. The risk of developing AMC increases in siblings of 
an affected child either with AMC or neonatal MG, and is not dependent on the mother’s 
clinical state. [90]  
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Thymectomy 
Despite the lack of evidence from well-controlled, randomized studies, thymectomy is well 
supported by long-term evidence, and is widely used as a treatment for MG. Different 
surgical techniques and concomitant use of immunosuppressants makes it difficult to 
evaluate precisely the effect of surgical intervention. According to the most recent 
guidelines for treatment of neuromuscular transmission disorders [65], MG patients 
undergoing thymectomy are twice as likely to achieve medication-free remission, 1.6 times 
as likely to become asymptomatic and 1.7 times as likely to improve. No study has reported 
a significant negative effect of thymectomy. The use of thymectomy in treatment of MG 
relates to the disease subtype: 
Ocular MG 
In absence of a thymoma, thymectomy is not recommended for MG patients with 
symptoms limited to ocular/periocular muscles [65, 91]. 
EOMG:  
These patients are considered the main target for thymectomy, as they have an enlarged 
and hyperplastic thymus. Thymectomy should be performed early in the course of the 
disease in patients not experiencing full remission after administration of AChE-Is, in order 
to prevent the peripheral seeding of autoreactive T cells [16]. 
LOMG: 
Thymic abnormalities are only seen in a minority of patients in this group. The patients with 
an enlarged and hyperplastic thymus are usually middle-aged, with disease manifestations 
resembling EOMG, and should probably be treated as such. Absence of antibodies to titin 
and RyR increases the chance for a positive effect of thymectomy [16]. 
Thymoma MG 
All patients diagnosed with a thymoma should undergo thymectomy irrespective of MG-
related symptoms. The focus of treatment is directed at removing the tumor, rather than 
gaining improvement of MG symptoms [65]. Surgical removal is sufficient for non-invasive 
thymomas [16]. 
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Anti-MuSK MG 
Thymectomy in anti-MuSK positive MG is associated with poor outcome [92], or has not 
shown any effect [93]. It is in most centers not recommended for patients with anti-MuSK 
MG. 
Seronegative MG 
Thymectomy as treatment of seronegative MG is controversial, and the discovery of low-
affinity antibodies has made this group more heterogeneous [30]. Studies have shown an 
effect of thymectomy in this group to be similar to what was observed in seropositive MG 
[94-95]. Investigations on the effect of thymectomy in patients with low-affinity antibodies 
have not been performed. Seronegative MG patients with early onset and an enlarged 
thymus should probably be treated as EOMG patients.  
Myasthenic crisis 
Traditionally, myasthenic crisis (MC) is defined as an acute worsening of MG causing 
respiratory failure and the need for hospitalization and ventilator support. A variety of 
conditions, including infection, surgery, systemic illness, fever, emotional stress, pregnancy 
and certain drugs, can exacerbate symptoms in MG patients. At least 70% of cases of MC are 
caused by infections. The development and the progression of the condition can be rapid, 
necessitating close observation in specialized care units. [96] 
Patients with MC present with respiratory stress and worsening of MG-symptoms. In 
patients known to have MG, the diagnosis can be readily made, whereas undiagnosed 
patients may require a more extensive diagnostic work up, as previously described. 
Pulmonary function should be assessed at least every four to six hours with peak air flow 
measurements and/or arterial blood gas examination. [96] 
When treating MC, the primary goal is to establish an adequate mechanic respiratory 
support and, if necessary, to stabilize the patient via other standard intensive care unit 
procedures. This should precede pharmacological treatment options. The use of AChE-Is in 
treatment of MC have been reviewed [96]. In critically ill patients, oral absorption and drug 
half life may be altered and over dosage may cause increased weakness and interfere with 
extubation. However, no randomized, controlled trials have been done to investigate the 
efficacy of AChE-Is in treating MC.   
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Plasmapheresis and IVIG are both equally effective treatment options in worsening MG [84]. 
IVIG tend to be preferred because of the cost, potential side-effects of PE, and a simpler 
procedure. However, PE shows a slightly higher responder rate, and probably a slightly more 
rapid onset of action [96-97]. High-dose intravenous methylprednisolone has been 
suggested to be beneficial in short-term treatment of MG [61], and can be combined with 
either PE or IVIG [96]. 
After successful treatment of MC, long term immunosuppressive treatment is 
recommended to maintain the improvement from PE or IVIG. Prednisolone, which is 
gradually tapered until minimum effective dose is reached, together with AZT is usually 
chosen [65]. If stopped during MC treatment, the re-inctroduction of AChE-Is should follow 
patient remission and stabilization. 
Myasthenia Gravis and the heart 
Reports on cardiac abnormalities in MG patients are numerous, but no causal link has been 
found. Almost half of all MG patients and 97% of thymoma-MG patients have antibodies 
towards heart muscle antigens [98], and serum from some MG patients binds to conductive 
tissue in heart [37]. Antibodies targeting adrenergic β-receptors [36] and muscarinic AChRs 
[99] have since been identified. Myocarditis in MG patients, even in the absence of cardiac 
symptoms, has been demonstrated [100-105]. These cases are most often associated with 
thymoma MG.  
Electrocardiogram (ECG) changes in MG patients have been thought to reflect cardiac 
conduction abnormalities possibly related to the disease. However, many types of 
abnormalities have been observed, and they are not MG-specific. The ECG changes include 
inverted T-waves and ischemic-like ST-segment abnormalities [106], QT-prolongation [107],  
systolic time interval abnormalities [108], terminal notching of the QRS-complex [109], right 
bundle branch block and arrhythmias [110]. However, not all studies performed have been 
able to find convincing ECG changes in MG patients [111]. Together, these observations are 
regarded as indicative of altered cardiac conduction in MG patients. As the changes are 
diverse and not specific for MG, the role of ECG in the assessment of MG-associated heart 
disease is uncertain. 
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Claims of reduced cardiac function were published in 1992. Johannessen et al. found 
reduced diastolic filling rate, but normal ejection fraction (EF), in a group of 25 MG patients 
without known heart disease [112]. Another study published a few years later observed a 
40% post-exercise drop in global EF among the MG patients studied [113]. A recent study 
from our research group could not reproduce these observations, but found pyridostigmine-
reversible reductions in atrioventricular-plane velocity and tissue Doppler peak systolic 
strain between MG patients and controls [114]. 
These reports and the knowledge of existing antibodies capable of binding to cardiac tissue, 
offers an array of theoretical mechanisms on how cardiac function may be affected in MG: 
Antibody mediated disturbances in conductivity could lead to arrhythmias, antibodies 
towards RyR may interfere with calcium handling in cardiomyocytes and alter cardiac 
inotropy, and interference with mAChRs may give rise to autonomic dysregulation with 
subsequent impaired cardiac function. Recognition of epitopes on heart muscle by the 
immune system could induce an immune mediated attack on the myocardium with 
complement activation, inflammatory cell infiltration and cell death as a consequence.  
In several of the previously mentioned studies, the observed changes in heart function 
among the MG patients were reversible by pyridostigmine [108, 112, 114]. The effects of 
AChE-Is on cardiac function have been demonstrated through both invasive and non-
invasive procedures. A single dose of 45mg pyridostigmine increased the ventricular 
refractory period during high heart rate in patients undergoing intracardial 
electrophysiological examinations [115]. However, the patients included in this study were 
suspected of having heart disease and used a variety of other medications. Dewland et al. 
examined the effect of 30mg pyridostigmine on healthy subjects, either well trained or 
sedentary, and found an effect on resting heart rate and post exercise heart rate recovery in 
the sedentary individuals only [116]. It thus seems that AChE-Is have an effect on cardiac 
function, but it remains unclear whether this is because AChE-Is act on the myocardium 
directly or through altering the autonomous nervous system. The differences between MG 
patients and controls in response to intake of AChE-I could also be explained by down-
regulation of AChRs in MG-patients that are being treated with AChE-Is. When the drug is 
withdrawn before the study, its effects when re-initiated would be less than in control-
subjects. Nonetheless, the observation that AChE-Is affect cardiac function in MG patients, 
29 
 
but not in controls, clearly suggests that there is AChE-I responsive changes in cardiac 
function in MG patients.   
Heat Shock Proteins  
The heat shock response was first described by Ritossa in the early 1960s [117]. By mistake 
he incubated Drosophilia at higher temperature, and observed a different chromosomal 
puffing pattern. He noted that this response was rapid, occurring within minutes, that a 
similar pattern occurred in other species, and that mitochondrial uncouplers and anaerobic 
conditions produced the same response [117]. Since then a various of stimuli have been 
shown to induce the heat shock response, including amino acid- and glucose analogs, heavy 
metals, protein kinase C stimulators, calcium increasing agents, ischemia, microbial 
infections, hormones and antibiotics, but the name heat shock persists [118]. The heat 
shock proteins (Hsp) are divided into subfamilies according to weight [119], and play a 
crucial role as chaperones in protein folding and maintaining endoplasmic reticulum 
homeostasis [120].  In addition, the HSPs are believed to have immunostimulatory 
properties, both by means of antigen presentation, but also per se.  
During the last 10 years, numerous reports on the immunological role of Hsp70 and other 
Hsps have been published. The immunological response to Hsp70 stimulation is widespread 
and includes dendritic cell maturation and increased cytokine production [121], receptor 
mediated monocyte activation with subsequent increased expression of pro-inflammatory 
cytokines [122], activation of Natural Killer cells increasing their lytic capacity [119]. Hsp70 
and Hsc70 (the constitutively expressed form of the protein) have been shown to chaperone 
immunogenic peptides into the MHC class I antigen presenting pathway [123]. In addition to 
being an intracellular chaperone, reports on increased efficacy in antigen presentation, 
possibly through extracellular chaperoning have been published [124].  
One theory regarding peptide-free Hsp70 activation of the innate immune system is that 
Hsp70 can act as a danger signal in a situation of necrotic cell death, with release of Hsp70 
to the surroundings. This implies that the immune system reacts to the dangerous situation 
rather than to the presence of foreign or non-self antigens [125].  
However, some concern has arisen around the role of Hsp70 in immunological signaling. 
Hsp70 is usually acquired through genetically modifying Escherichia coli to express human 
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Hsp70 cDNA, and the final product may be contaminated with bacterial products, such as 
lipopolysaccharide (LPS) and lipoprotein. In fact, the observed Hsp70 signaling pathways, i.e. 
Toll like receptor 2 and -4, are the same as LPS [126]. Some studies which used Hsp70 of 
bacterial origin demonstrated effects of Hsp70 using nanogram quantities of the protein 
[122, 124], whereas Hsp70 purified from liver, had no effect even when used in 100-1000 
fold greater concentration [127]. To circumvent the possibility of contamination, heat 
inactivation (to remove Hsp70 activity) and polymyxin-B (to inhibit LPS) treatment of the 
preparations have been used. These measures are by some considered inadequate, as LPS 
have been shown to be heat sensitive, and because contaminants other than LPS may be 
present [128]. 
The contamination issues make it difficult to interpret many of the studies, and force 
scientists to put more thought and effort into the process of how Hsp70 is acquired. The use 
of eukaryotic cells for Hsp70 expression to avoid contamination with pathogen associated 
molecular patterns (PAMP), such as LPS, is an alternative approach. Recombinant Hsp70 in 
combination with IL-2 stimulates several subsets of T-lymphocytes to produce a range of 
cytokines and induce proliferation of CD4+ T-cells. Granzyme B mRNA levels, along with 
secreted amounts of protein, were significantly increased by Hsp70 in CD3+, CD4+ and CD8+ 
T-cells [129]. In mice, anti-Hsp70 applied epicutaneously before treatment with an allergy 
inducing agent caused a systemic tolerance to the agent. The mice were able to mount an 
immune response to other allergy inducing agents, and the tolerance could be adoptively 
transferred when using spleen cells [130]. This provides both direct and indirect evidence 
that Hsp70 does play a role in immunoregulation, but the signaling pathways and -effects 
may be different from originally reported. 
Involvement in disease:  
Hsp70 is believed to be involved in the pathogenesis of several autoimmune disorders. 
Increased levels of anti-Hsp70 are observed in Behçet's disease (BD) together with increased 
levels of free Hsp70 [131]. This study included patients with RA and recurrent oral 
ulcerations in addition to healthy individuals as controls. All patient groups had increased 
levels of free Hsp70 compared to healthy controls, but only BD patients had increased 
concentrations of Hsp70-antibodies. 
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In patients with Grave’s disease, the 8.5kb PstI HSP70 allele has been shown to be 
associated with the disease. Furthermore it was found that, in both patients and controls, 
the presence of the allele was strongly associated with deletion of the C4A gene, encoding 
serum complement factor 4a. However, the frequency of the 8.5kb PstI HSP70 allele 
remained higher in Grave’s patients than in controls also in the absence of the C4A gene 
deletion, suggesting that the HSP70 locus may have immunological properties [132]. 
Another genetic study has also demonstrated weak association between certain HSP70 
polymorphisms and Grave’s disease [133]. 
Multiple sclerosis patients have increased levels of antibodies against Hsp70 and Hsc70 as 
well as DnaK (the bacterial homologue of Hsp70) when compared to patients with motor 
neuron disease [134]. The anti-Hsp70 and anti-Hsc70 antibodies were not specific in binding 
only to one of the proteins. There was only a partial overlap between the anti-Hsp70/anti-
Hsc70 “antibody pool” and antibodies binding to DnaK. CSF from MS patients with high titer 
of antibodies was capable of inducing IL-8 and TNF-α production in vitro when administered 
together with Hsp70, but this did not apply for CSF from Guillain-Barré syndrome (GBS) 
patients, even though such sera is known to have high titers of anti-Hsp70 [134]. A higher 
proportion of T lymphocytes from MS patients than from healthy controls react to Hsp70 
derived from Mycobacterium tuberculosis. T cell cross reactivity with human Hsp70 derived 
peptides was also observed [135].  
In vivo studies in mice demonstrated the properties of Hsp70 as an adjuvant in inducing 
cytotoxic T cell mediated destruction of pancreatic islet β-cells causing diabetes [136]. 
Experimental autoimmune neuritis (EAN) is an animal model for studying GBS. Thirteen days 
post immunization with a neuritogenic peptide, there was an increase of Hsp70 positive cells 
in the sciatic nerves accompanied by an increase in Hsp70 mRNA in cells from the sciatic 
nerve and from lymph nodes [137]. Antibodies against HSP70 family members have been 
detected in sera from patients with sensory neuronal hearing loss [138], systemic lupus 
erythematosus [139], juvenile idiopathic arthritis [140] and MG [141]. These studies have 
focused on the presence of antibodies, and have not aimed at providing any etiological 
evidence. 
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The other study which addressed antibodies towards members of the HSP70 family in MG 
patients, tested for antibodies against heat shock cognate protein 71 (Hsc71) [141], also 
known as heat shock 70kDa protein 8, according to the HUGO Gene Nomenclature 
Committee. They found that the anti-Hsc71 antibody levels decreased in patients when they 
had improved on therapy. Therapy, however, included both immunosuppressants and 
plasmapheresis. By not specifying which patients received what kind of treatment, it is 
difficult to conclude whether the decline in antibody titers was a result of 
immunosuppression or plasmapheresis, or whether the antibody decline is the cause or the 
effect of improvement.  
Matrix Metalloproteinases  
The matrix metalloproteinases (MMP) is a group of 23 zinc-dependent enzymes [142-143]. 
They act as endopeptidases capable of cleaving a range of extracellular matrix (ECM) 
proteins as well as non-ECM substrates. Most cells synthesize MMPs and secrete them 
immediately, whereas inflammatory cells can produce for storage. Originally named based 
on their substrate specificity, the enzymes are now named MMP-1 through -26, with no 
MMP-4, -5 or -6. Most MMPs share a pro-domain and a catalytic domain, where the 
catalytic domain contains the zinc binding site [144]. The MMP-group consists of both 
membrane bound and secreted proteins [143].  
The MMPs both as a group and as individual enzymes have an array of potential substrates, 
including ECM components (i.e. collagens, elastin, fibronectin, laminin), coagulation factors 
(i.e. fibrin, fibrinogen), immunoactive proteins (i.e. IL-1β, IL-8, pro-TNF, complement factors) 
and other MMPs [142-143]. The wide substrate specificity has potential deleterious effects 
if not properly regulated. The secreted MMPs are often bound to proteins on the cell 
membrane, limiting their area of impact to the pericellular space [143].  It has been shown 
that cells are able to determine the localization of different substrates through binding to 
surface receptors, and that the secretion of MMPs is directed to the area where substrate-
receptor binding occurred [145].   
Expression of MMPs is normally low in tissues, but increases during conditions requiring 
remodeling of the ECM [146]. Main, but not sole, regulation of MMP gene expression occurs 
at the Activator Protein-1 (AP-1) binding site, found in the promoter region of the inducible 
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MMP genes [147]. AP-1 complexes are heterodimers of members of the protein families jun 
and fos. Co-transfection of jun and fos enhances MMP-1 expression, and c-fos is required for 
induction of mouse MMP-3 and MMP-13 gene expression [143]. The promoter sequence of 
the inducible MMP genes also contains polyoma enhancer A binding protein-3 (PEA3) 
elements that bind ETS transcription factors, which are  believed to be coactivators when 
forming complexes with factors binding to AP-1 [146]. Several stimuli converge onto these 
regulatory elements through intracellular kinases: Growth factors and mitogens activate the 
ERK1,2 pathways, oxidative and osmotic stress stimulates the ERK5,6 pathways, and the jun 
N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is stimulated by 
environmental stress and inflammatory cytokines [143]. Altough primarily regulated on the 
transcriptional level, regulation downstream of transcription, such as modulation of MMP 
mRNA stability, has been reported [148].  
MMPs are secreted in a pro-form, requiring activation, often through catalytic cleaving, in 
order to exert its function. Activation is achieved through various enzymes, such as plasmin, 
urokinase plasminogen activator and tissue-type plasminogen activator, but also through 
proteolysis by other MMPs. The biochemical reason for this mode of activation relies in the 
blocking of the catalytic site by a cysteine residue (Cys73) in the pro-domain of the enzyme. 
This Cys73 is common for most MMPs. Dissociation of the cysteine residue from the zinc 
atom in the active site, either through protein denaturation (e.g. by use of SDS or 
organomercurials) or through proteolytic cleaving (by other proteases or auto-proteolysis), 
activates the MMP. This process is called Cysteine Switch Mechanism [143].  
Two types of ambient inhibitors of the MMPs exist, the four variants of tissue inhibitors of 
metalloproteinases (TIMP1-4) and the inhibitors of metalloproteinases (IMPs). These factors 
inhibit all types of MMPs by binding to the active site of the enzyme. Although all are broad 
spectrum MMP inhibitors, some differences exist in terms of MMP-specificity, mechanism of 
action and ability to inhibit other types of proteinases. The MMPs are also inhibited by the 
general proteinase inhibitors α2-macroglobulins [149].  
Involvement in disease:  
In RA, MMP3 is increased in both serum and synovial fluid compared to the levels in 
patients suffering from degenerative osteoarthritis. The elevated serum levels correlated 
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with degree of MMP3-immunostaining and immune cell infiltration in synovial tissues, 
suggesting that the serum level increase was due to local production in inflamed joint 
tissues. Knee replacement surgery caused a decline in MMP3 levels, which were maintained 
for up to 4 weeks, further supporting the local production theory [150]. In addition to 
MMP3, MMP2 and MMP9 serum levels and enzymatic activity are increased in RA patients 
[151]. The increased MMP3 levels in RA was confirmed in another study where RA patients 
were used as controls when examining serum levels of MMP3 in patients with systemic 
lupus erythematosus (SLE), in particular SLE patients with active renal disease with 
biochemical signs of renal involvement (persistent proteinurea, cellular casts, decreased 
creatinin clearance, and serum uric acid levels) [152]. MMP2 and -9 levels and activity are 
also increased in SLE patiens [151]. Matache et al. found increased levels of spontaneously 
released MMP9 from peripheral blood mononuclear cells (PBMCs) but unchanged levels of 
secreted TIMP-1 from patients with SLE, providing a potential source for the increased 
MMP9 levels [153].  
Both the concentration and enzymatic activity of MMP9 is increased compared to healthy 
controls in saliva and in biopsies from the salivary glands of Sjögren's Syndrome (SS) 
patients. When comparing biopsies from healthy controls and the SS patients, there was no 
difference in expression patterns of either MMP9 or MMP2. However, some neutrophils 
showed intense MMP9 staining in the SS group only [154]. Patients with primary SS with 
severe sialadenitis had increased local MMP3 expression in minor salivary glands compared 
to patients with secondary SS [155]. Salivary gland expression of MMP2, -3 and -9 together 
with TIMP-1 and -2 have also been assessed by means of RT-PCR and western blotting from 
salivary gland biopsies, and showed MMP3/TIMP-1 and MMP9/TIMP-1 ratios above 1, with 
the latter being the highest. Acinar changes seemed to correlate with increased 
enzyme/inhibitor-ratio, suggesting that MMP9 accounts for the main proteolytic activity of 
the enzymes measured [156].  
Several of the MMPs have been thoroughly studied in patients with MS and in MS models, 
mainly experimental autoimmune encephalitis (EAE). CSF samples from MS patients have 
increased levels of MMP2 and -9 [157-159], and MMP9 serum expression correlates with 
disease activity measured by means of MRI and clinical evaluation [159-160]. The MMP9 
increase has been shown to precede the appearance of new gadolinium enhanced lesions 
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on MRI [161]. This, in addition to the observation of MMP2 and -9 expressing macrophages 
and lymphocytes around perivascular cuffs [162], is fueling the theory that MMP9 is 
important in immune cell migration across the blood brain barrier. Support for the role of 
MMP9 in MS development comes from animal studies in which young MMP9 null mice were 
less susceptible to develop EAE than wild type controls. A compensatory increase in MMP9 
was observed in MMP2 null mice which developed a more severe disease with earlier onset 
than controls, whereas MMP2 and -9 double null mice failed to develop any disease at all 
[162].   
MMP3 levels are increased in serum from patients both with seronegative and seropositive 
MG. In mice with experimentally induced MG through immunization with a synthetic 
peptide from the human AChR, treatment with a dual altered peptide ligand caused 
decreased T cell mediated MMP9 activity [163].  
In experimental autoimmune neuritis (EAN), an animal Guillain–Barré syndrome model, 
MMP2 and -9 mediated breakdown of β-dystroglycan has been shown to contribute to the 
development of the disease. The α/β-dystroglycan complex harbors an important role in 
myelin formation and stability, and disruption of this complex can lead to peripheral 
nervous system dysmyelination. Increased levels of MMP2 and -9 were found, using 
western blotting and immunohistochemistry, in sciatic nerves of EAN rats compared to 
control animals. Using captopril as an MMP inhibitor from the time of disease induction, the 
captopril-treated animals developed a milder disease phenotype with less demyelination, 
less β-dystroglycan cleavage, less MMP2 and -9 expression and reduced sciatic nerve 
inflammatory cell infiltration [164].   
This review shows that MMPs play an important role in autoimmune diseases. Judging from 
the variety of different immunological diseases with increased levels of the enzymes, MMP 
effects are not disease specific.  
Guillain-Barré syndrome  
Guillain-Barré syndrome (GBS) is an autoimmune peripheral nervous system disorder. It 
consists of at least four subtypes, with the acute inflammatory demyelinating 
polyradiculoneuropathy (AIDP) type being the most common. The disease occurs after an 
infection with campylobacter jejuni in 25% of cases, due to similar peptide sequences 
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occurring in the peripheral nervous system and in the bacterial wall. In AIDP it is believed 
that the myelin breakdown occurs either through T-cell mediated activation of macrophages 
or due to antibody-binding and complement mediated attack on the Schwann cells. Axonal 
damage is not a dominating feature, but can occur as a secondary phenomenon if the 
demyelination is severe. In acute motor axonal neuropathy (AMAN), and in acute motor and 
sensory axonal neuropathy (AMSAN), the macrophages are activated through Fc mediated 
binding of antibodies targeting antigens on the axonal membrane, leaving the myelin 
sheaths intact.   
The initial symptoms are typically pain, numbness, paraesthesias or weakness in the limbs, 
most often starting distally with proximal spreading as the disease progresses. Autonomic 
involvement is common and may give rise to symptoms such as hypertension, urine 
retention, ileus, sinus tachycardia and arrhythmias. Progression of the weakness can cause 
respiratory difficulties. The deteriorating phase of the acute disease lasts for 2-3 weeks, 
after which the patient enters a plateau phase and then begins to recover. The prognosis for 
AIDP is generally good, but some patients will not experience a full recovery [165]. 
Treatment includes plasmapheresis and intravenous immunoglobulins [166]. Corticosteroids 
are considered ineffective for AIDP [167]. 
  
  
37 
 
AIMS OF THE STUDY  
 
1. To assess the potential cytotoxic properties of MG sera in vitro on various cell types. 
(papers I and II) 
 
2. To measure potential non-antibody, disease mediating factors in MG (papers III and 
IV) 
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MATERIALS AND METHODS  
Patients and controls 
The MG diagnosis was made based on the clinical presentation of symptoms, presence of 
AChR antibodies in serum and electrophysiological findings (presence of >10% decrement of 
the compound action potential using repetitive stimulation at 2-3 Hz, and increased jitter 
using single fiber electromyography). Patients included in paper I and II were diagnosed at 
the Department of Neurology, Haukeland University Hospital, Bergen, Norway whereas the 
patients in paper III and IV were diagnosed with MG at Moorfields Eye Hospital, Neuro-
ophtalmology Clinic, London, UK, and followed by Gordon Plant (co-author on papers III and 
IV).  
Control sera included Norwegian blood donors (for papers I – IV), Norwegian GBS patients 
and Norwegian MS patients (paper III and IV). The GBS and MS patients were all diagnosed 
and followed by physicians at Department of Neurology, Haukeland University Hospital. The 
MS diagnosis was made based on the Poser criteria [168]. GBS patients were diagnosed 
according to Asbury and Cornblath’s clinical criteria [169].  
All patient samples used in the experiments reported were collected and stored as 1-2 ml 
aliquots below -20°C. 
Cell culture 
All cell culture experiments were performed in sterile conditions using properly maintained 
laminar air flow benches. For incubation of cells water jacketed incubators set to 37°C with 
5% CO2 / 95% O2 were used. Culturing media was stored and supplemented when needed 
according to the manufacturer, and heated to 37°C using a water bath before application. 
Cell viability assays (paper II) 
Cell viability was quantitatively measured using two different methods:  
Adenylate Kinase (AK) release assay [170] 
The enzyme AK is released upon the loss of cell plasma membrane integrity when cells are 
cultured in vitro. The amount of AK released into the growth medium will reflect the degree 
of cytotoxicity. The kit used (ToxiLight®, Cambrex (previously Lonza)) relied on a two step 
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process for detecting the amount of AK released. The first step is catalyzed by AK and 
provides ATP for assay bioluminescence, whereas the second step is catalyzed by Luciferase 
and produces light from ATP and luciferin.  
Mg++ADP + ADP ↔ Mg++ATP + AMP 
ATP + Luciferin + O2  Oxyluciferin + AMP + PPi+ CO2 + Mg ++ + LIGHT 
The emitted light intensity is related linearly to the concentration of AK in the medium, and 
can be measured on a luminometer. 
Annexin-V-Fluos kit [171] 
This assay uses Annexin-V-FITC and Propidium Iodide (PI) to stain the cells before they are 
examined using a flow cytometer. When a cell undergoes apoptosis, phosphatidylserine (PS) 
is translocated from the inner to the outer side of the plasma membrane, while the plasma 
membrane integrity remains intact. Annexin-V is a Ca2+ dependent phospholipid binding 
proteins with high affinity for PS, thus making it suitable for labeling cells undergoing 
apoptosis when conjugated to a fluorescent dye. The flipping of PS to the outer membrane 
also occurs during necrosis, but contrary to apoptosis, the plasma membrane does not 
remain intact. To differentiate apoptotic from necrotic cells, PI is used to stain DNA, as it will 
not penetrate an intact plasma membrane [172]. After labeling the cells according to assay 
instructions [171], the cells (10.000 readings per sample) were examined on a BD FACS Aria 
SORP flow cytometer (BD Biosciences, San Jose, CA, USA) using 488 and 532 nm lasers with 
525/50 and 610/20 bandpass filters, respectively. Treatment of the cells with 0.01 M H2O2 
for 24 hours served as a positive control, from which the appropriate gating was performed.  
Antibody assays (papers III and IV) 
In paper III, anti-Hsp70 antibody total (IgG, IgM and IgA) concentrations were measured 
using anti-Human Hsp70 ELISA kit (Stressgen, MI, USA). Preparation of serum samples and 
incubation times were performed according to assay instructions. According to the 
information given by the manufacturer, the sensitivity of the assay was 6.79 ng/ml. Both the 
inter- and intra-assay coefficient of variation was <10%. All readings were within the 
standard curve. 
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For the measurements of MMP2, -3 and -9 levels in paper IV, Quantikine Human Total 
MMP2, -3 and -9 ELISA Kits (R&D Systems, Minneapolis, MN, USA) were used according to 
assay instructions. Sensitivity (mean minimum detectable concentration) and intra- and 
inter-assay coefficient of variation for the assays were as stated in Table 1. All readings were 
within the standard curve. 
  Coefficient of variation 
 Sensitivity 
(ng/ml) 
Intra-assay Inter-assay 
MMP2 0,16 4,80 % 7,70 % 
MMP3 0,009 6,10 % 7,80 % 
MMP9 <0,156 2,30 % 7,50 % 
Table 1: Precision of ELISA assays used in paper IV. Numbers are supplied by the 
manufacturer. 
 
The optical density for all assays was measured at 450nm with 590nm correction using 
Thermo Multiskan EX plate reader. 
In vitro live cell calcium measurements 
The results from these experiments are not included in the four papers for which this thesis 
is based upon. This project was partly a continuation of the work performed by Skeie et al., 
where he showed that anti-RyR antibodies can inhibit binding of ryanodine to the receptor 
[41], and this can inhibit calcium release from terminal cisternae fractions [173]. Finally, MG 
patients with antibodies towards RyR have a more severe MG, than the anti-RyR negative 
MG patients [174]. The possibility of a pathogenic role for the RyR antibody in MG, led us to 
trying to establish a model for measuring the effects of the antibody on calcium release in 
live muscle cells.  
Skeletal muscle cells (human skeletal muscle myoblasts (HSMM) (Lonza, Switzerland) and 
C2C12 muscle myoblasts (Sigma-Aldrich, Norway)) and  were seeded onto No. 0 35 mm 
glass bottom culture dishes (MatTek Corporation, Ashland, MA, USA), grown to confluency 
and differentiated for 3-7 days. Differentiation media contained DMEM supplemented with 
41 
 
2mM L-glutamine and 2% horse serum. After differentiation, the cells were maintained in 
appropriate growth media for 3-5 days. Immediately before the experiments both cell types 
were loaded with 1-2μg/ml Fura-2-acetoxymethyl ester (Invitrogen) at room temperature 
for 60-120 min before a 30-60 min de-esterification period at 37°C.  
The glass bottom dishes were fitted in a custom made, heated perfusion chamber frame on 
the stage of an Olympus IX-70 with a x40 UAPO objective. A gravity driven perfusion system 
passing through a Warner TC344-B perfusion inline heater fed the perfusion chamber at 2 
ml/min while maintaining the chamber temperature at 36-37°C. Switching between fluids 
was done automatically with magnetic valves. Regions of interest (ROI) were defined using 
the image analysis software and drawn along the borders of cells displaying an elongated, 
multinucleated phenotype. Background fluorescence was measured in areas adjacent to the 
cell ROIs and subtracted from the recordings.  
Alternating excitation with 340 nm and 380 nm wavelengths was performed using a dual-
excitation wavelengths system (Delta-Ram) from Photon Technologies (PTI). The signal 
passed through a 510 nm low pass filter before being recorded by an IC-200 intensified CCD 
camera with at a frequency of 1,6Hz. Image Master (PTI) software was used to calculate the 
ratio between the 510nm signals obtained from excitation with 340 and 380nm wavelengths 
using the following formula: 
 ࡾࢇ࢚࢏࢕ ൌ ૜૝૙࢔࢓ࢉࢋ࢒࢒ି૜૝૙࢔࢓࢈ࢇࢉ࢑ࢍ࢘࢕࢛࢔ࢊ
૜ૡ૙࢔࢓ࢉࢋ࢒࢒ି૜ૡ૙࢔࢓࢈ࢇࢉ࢑ࢍ࢘࢕࢛࢔ࢊ
  
The cells were perfused with perfusion buffer adjusted to pH 7.4 containing 137mM NaCl, 
5.4mM KCl, 0.5mM MgCl2, 1.8mM CaCl2, 11.8mM HEPES-NaOH and 1g/l glucose for at least 
3 minutes until a one minute stable baseline ratio was obtained. Caffeine (Sigma-Aldrich, 
Norway) was dissolved in perfusion buffer to a final concentration of 0.1, 1 and 10mM to 
stimulate calcium release from the cells [175-177]. Dantrolene 5μM was included as a 
negative control.  
Statistical methods 
Differences between patients and controls in paper II were assessed using one-way analysis 
of variance (ANOVA). 
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Normality assessment for continuous variables in papers III and IV was performed using the 
Anderson-Darling test. 
The choice of a statistical test for group comparison in papers III and IV depended on the 
outcome from the normality assessment. If normality was present, continuous variables 
were compared using a two-sample t-test. In cases of non-normality distribution, the Mann-
Whitney U test was employed.  
A confidence interval of 95% was used as significance level in all experiments.  
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SUMMARY OF RESULTS  
Morphological and cytotoxic effects of Myasthenia Gravis patient sera on 
human cells in culture (papers I and II) 
Of the 13 MG patient sera tested on primary human myotubes (paper I), 2 sera (denoted a 
and b) were able to induce dramatic morphological changes in the muscle cells. The 
myotubes transformed from an organized elongated phenotype to appearing in a 
disorganized, contracted and irregular pattern. In addition, perinuclear inclusion bodies 
appeared. The factors responsible for these changes had molecular weight above 100kDa. 
Sera a and b also caused a decrease in cell number when incubated over a period of three 
days. As myotubes are multinuclear, the number of DAPI-stained nuclei was used to assess 
cell number. Serum from a third MG patient, where serum was drawn during a MG crisis, 
just as for serum a and b, also caused morphological changes and formation of inclusion 
bodies, but to a lesser degree. Nine of the remaining 10 patient sera caused a varying 
degree of morphological changes, ranging from mild to moderate, and a lesser degree of 
inclusion body formation than what was observed in sera a – c. However, they were all 
different from controls. Cells treated with serum from one MG patient (m) were 
indistinguishable from controls.  
Serum b caused membrane blebbing in the myotubes. DAPI-staining following treatment 
with MG sera revealed intranuclear vesicle-like structures, which could not be seen in the 
nuclei of cells treated with control serum. The sera which caused the most marked 
morphological changes using CV staining also led to a disorganization of the actin 
cytoskeleton, with the actin fibers running in multiple directions. The less potent MG sera 
were able to induce some disturbances in the actin organization, but not to the same extent 
as sera a and b.    
The changes observed were dose- and time dependant. The formation of inclusion bodies 
occurred after 24 hours, after which retraction of the cell membrane, formation of discrete 
multicellular clusters  of cells and a progressive loss of cell number over 4 days occured. Sera 
diluted 1:10 were more potent in inducing cellular changes than sera diluted 1:100. 
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Heat-inactivation of the sera did not inhibit the observed changes and indicates a non-
complement mediated mode of action.  
Given the results in paper I and the abundance of reports suggesting a link between cardiac 
disease and MG, we expected to observe a morphological and/or cytotoxic effect of human 
MG sera on cultured human heart cells.  However, none of the 15 MG sera included in our 
experiments caused morphological changes. No differences in cell number after incubation 
with sera from patients and controls could be seen. The relative level of AK released from 
cells treated with MG sera did not differ from healthy human control sera. Assessment of 
cell death and apoptosis induction by MG sera was performed by Annexin-V- and PI-staining 
and flow cytometry. Control sera induced cell death in 8.4% of the cells, measured as 
percentage of cells positive for PI-staining. This did not differ from the 9.3% PI-positive cells 
after treatment with MG sera (p=0.694). Less than 1% Annexin-V positive cells could be 
detected in both patients and healthy controls, indicating no apoptosis activation (Figure 1).  
 
Figure 1: Dot plots of Girardi cells stained with Annexin-V-FITC and PI after 24 hours 
treatment with human control sera (a), 0,01M H2O2 (b) and sera from 4 different MG 
patients (1 seronegative (c) and 3 seropositive (d-f)). Double negative cells are regarded as 
live, whereas PI positive cells are counted as dead cells. The selected patient plots are 
representative for all MG sera tested. 
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The results in paper II were not dependant on serum incubation time or concentration. 
 
Potential non-antibody disease mediating factors in MG (papers III and IV) 
Sera from 129 MG patients were used for both paper III and IV. The MG patients included 
were categorized depending on their symptoms being restricted to the ocular and 
periocular muscles (ocular MG (OMG)) or affecting other muscles (generalized MG (GMG)). 
However, all MG patients had involvement of the ocular or periocular muscles, and in cases 
of generalized disease, the symptoms were mild. This is further discussed on page 50. The 
OMG and GMG groups were similar with regard to age, sex and presence of anti-AChR 
antibodies. Of the 94 GMG patients 36 had detectable levels of anti-AChR antibodies, 53 
were negative and 5 unknown. The OMG group had 16 anti-AChR positive, 18 negative and 
1 unknown. In paper III, sera from 37 patients with untreated GBS and 49 with untreated MS 
were included as disease controls. 41 blood donor sera were used as healthy controls in 
both papers.  
Both GMG and OMG patients had higher anti-Hsp70 levels than healthy controls, with 
median values being 271.0, 333.0 and 171.9 μg/ml, respectively, (p<0.001). They were also 
significantly higher than in the MS patients (p=0.0004). Median anti-Hsp70 concentration in 
GBS patients was 471.8 μg/ml, this being significantly higher than in all the other groups 
(Figure 2).  
No correlation between patients’ age at time of inclusion in the study and anti-Hsp70 levels 
was found. As all patients included in the study had received their MG diagnosis within the 
last two years before serum was drawn, age at inclusion was used to categorize patients 
into either EOMG or LOMG.  
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Figure 2: Box plot illustrating the anti-Hsp70 antibody concentrations in OMG and GMG 
patients and controls. The boxes represent interquartile range (IQR). Outliers within 1.5 IQR 
of the boxes are marked with whiskers, whereas outliers between 1.5 and 3 IQR, and 3 IQR 
of the boxes are denoted Ο and *, respectively. 
 
 
When examining MMP levels in the MG patients, no difference between the OMG and GMG 
group or between the anti-AChR positive or negative patients was observed for either 
MMP2, -3 or -9. When comparing all the MG patients to controls, there were significantly 
higher concentrations in the patient group for MMP2 and -9 (Figure 3 and Table 2). The 
same difference could not be found for MMP3. It was noted that female MG patients had 
significantly lower MMP3 levels than the male MG patients (p=0.0002) and controls 
(p=0.0016). It was also noted that a subgroup of 19 patients had MMP3 values exceeding 
the maximum concentration measured for any of the controls, and by a factor of 1.4 – 2.7. 
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This MMP3-High group contained more male patients (15 vs. 4; p=0.01). This group did not 
differ with regard to MMP2- (p=0.95) or MMP9-levels (p=0.91), anti-AChR-status (p=0.33), 
age (p=0.62) or MG subtype (GMG vs. OMG, p=0.59) (Table 3). 
MMP2 concentration showed a significant positive association with increasing patient age 
(p=0.027). This age-dependence was not found for the other MMPs (MMP3: p=0.82; MMP9: 
p=0.25). 
 
 
Figure 3: Scatterplot of MMP-levels in MG patients and controls. A: MMP2, B: MMP3, C: 
MMP9 
 
 
Table 2: Median MMP-values with interquartile range in the 52 anti-AChR-positive and the 
71 anti-AChR-negative MG patients. Significance is compared to blood donor controls.  
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Table 3: 19 MG patients with MMP3-values exceeding the highest value in the control group 
(MMP3-High) compared to the rest of the MG patients (MMP3-Normal). (*Mann-Whitney U-
test, †Fisher’s exact test, ‡2-sample t-test, NS: Not significant) 
 
In vitro live cell calcium measurements 
Both HSMMs and C2C12 cells responded to caffeine stimulation with an increase in 
intracellular calcium levels. The effects appeared within seconds, and were dependent on 
the caffeine concentration used. Dantrolene inhibited caffeine induced calcium release 
effectively (Figure 4). Initially, human skeletal muscle myoblasts were used for the 
experiments. The responses obtained from caffeine stimulation were generally good, but 
the 340/380nm baseline ratio showed a high degree of variation between experiments. 
Also, these cells had a finite life span, and the caffeine responses seemed to decay when 
they were passaged more than 5 times. This rendered them unsuitable for further 
experiments.  
C2C12 cells are derived from mouse, and reports of caffeine induced calcium release in 
these cells have been published [177]. These cells were obtained from European collection 
of cell cultures through Sigma-Aldrich, ensuring their genuinity. Contrary to the HSMMs, 
C2C12 cells are a stable cell line. The caffeine response did not decay throughout passaging, 
as was observed with the HSMMs. However, the variations from one experiment to the 
other showed a high degree of variation. These variations occurred in cells treated similarly 
through passaging, differentiation, loading of FURA-dye and perfusion. Changes to the 
differentiation protocol; either through altering the differentiation time, changing the 
degree of cell confluency before differentiation, or prolonging the period of time the cells 
were maintained in growth media before starting the experiments did not improve the 
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results. Modifying the FURA loading protocol both with regard to incubation time and 
incubation temperature caused no decreased variation. 
Because we were not able to establish a stable system for measuring the changing calcium 
levels in live cells, the project was discontinued. 
 
 
 
Figure 4: Graph showing the ratio between 340nm and 380nm signals from 510nm excited 
FURA-stained human skeletal muscle myoblasts and the response to 10mM caffeine alone or 
in combination with 5μM Dantrolene.  
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GENERAL DISCUSSION  
The observation that some MG sera are cytotoxic to cultured human myoblasts indicates 
that serum factors in MG patients are capable of damaging muscle cells even though they 
lack a functioning neuromuscular synapse. Cultured skeletal muscle cells need neural stimuli 
to express the punctuate AChR expression pattern. This can be achieved either through co-
culturing skeletal muscle cells with cells originating from the spinal cord [178], or treating 
the muscle cells with agrin [179]. The mode of action was not complement mediated, as 
heat inactivation of sera had no effect, and the factors responsible for the observed changes 
had a MW >100 kDa. The separation of serum according to MW was achieved by means of 
centrifugal filtration through a Vivaspin filtration column with a 100 kDa membrane. This 
fraction includes all subclasses of antibodies, but does not contain most of interleukins and 
potential medications present in the patients’ sera.  
Sera from patients undergoing myasthenic crisis elicited the greatest effect in inducing 
morphological changes and reducing cell number, both compared to non-crisis MG patients 
and controls. During plasmapheresis the patients receives anticoagulant (heparin 
administered according to patients weight was used). Heparin (20 IU/ml medium) was 
therefore included as a control when treating the cells with plasmapheresis filtrate from 
crisis patients. Plasmapheresis serum from a patient with small cell lung cancer and limbic 
encephalitis with anti-Hu antibodies was used as a control, and had no effect.   
There was no apparent correlation between the anti-AChR status of the patients and the 
observed changes. A radioimmune assay was used to detect binding (as opposed to 
blocking) antibodies targeting the AChR [54]. Leite et al. published in 2008 results showing 
that 25 of 38 patients previously believed to be seronegative, in fact had low-affinity 
antibodies to the AChR. These antibodies could only be detected when subunits of the AChR 
were transfected and overexpressed in cells, to which the antibodies would bind [30]. The 
antibodies were mainly IgG1 subclass and could activate complement. Thus it is likely that a 
portion of the seronegative MG patients included in the studies in this thesis belong to the 
seropositive group, and this may have an impact on the conclusions drawn.  
In the UK MG patients, we noted that 45.7% of the OMG patients had detectable levels of 
anti-AChR antibodies. This is as expected for OMG [13]. In the GMG group, we found only 
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38.3% anti-AChR positive patients, which is much lower than the 80-90% commonly 
reported [9]. A reason for this may be that the patients included were recruited for the 
studies from a neuro-ophtalmology unit to which they were referred from other physicians 
due to weakness primary in the ocular and/or periocular muscles. Where there were 
generalized symptoms, they tended to be mild. We could find no differences between the 
GMG and OMG patients either with regards to anti-Hsp70 antibodies or MMP-levels. It is 
tempting to speculate that the GMG patients, in spite of having symptoms affecting muscles 
outside the ocular/periocular system, should be regarded as OMG patients. 
Antibodies against titin and RyR did not seem to play a major role for the cell culture 
response, as the three most potent sera were negative for either, although several of the 
sera with milder effects had anti-titin, and some also anti-RyR antibodies, although the 
present experiments made a major role less likely. One cannot rule out the possibility of 
these antibodies contributing to our observations or to the pathogenesis of MG. RyR has an 
important function in both skeletal and cardiac muscle in through Ca2+-release from the SR, 
regulating excitation-contraction coupling. Disturbances in the function of this protein can 
give rise to disease in both skeletal muscle, such as malignant hyperthermia [180], and 
cardiac arrhythmias [181]. Its involvement in MG is highlighted, beyond the presence of the 
antibodies per se, by the fact that MG patients with anti-RyR antibodies capable of inhibit 
ryanodine binding have a more severe disease than those with anti-RyR antibodies not 
inhibiting binding of ryanodine [41]. An argument against its role in pathogenesis is that the 
antigen resides intracellularly, and is not available for antibody-binding. Several papers are 
published on the topic of antibody internalization, but most of them have in common that 
the antibody in question binds to an extracellular antigen before being internalized [182-
183]. Internalization of antibodies against intracellular antigens has been reported [46, 184], 
and we cannot rule out the possibility that similar mechanisms take place in the course of 
MG.  
The possibility of anti-RyR antibodies playing a pathogenic role in MG led us to trying to 
establish a model system for measuring the potential effect of these antibodies on calcium 
handling in muscle cells . FURA-2 was used to detect intracellular calcium levels. This is a 
ratiometric fluorescent dye which binds to free calcium. The calculated ratio of fluorescence 
emitted when FURA-2 is excited with 340 and 380nm gives a relative calcium concentration. 
52 
 
Two different muscle cell lines were used; one human and one murine. Stimulation of the 
cells with caffeine gave an increase in intracellular calcium, and the effect was effectively 
inhibited with Dantrolene. However, the caffeine responses varied significantly between 
experiments, and we were not able to obtain reproducible and predictable baseline 
recordings. Multiple adjustments were applied to the cell differentiation protocol, growth 
medium, FURA-2 loading protocol and perfusion protocol, but to no avail. The integrity of 
the mechanical setup was ensured by others using the same equipment and getting stable 
readings. These experiments have not been published. 
The UK MG patients were categorized as early or late onset MG patients according to their 
age at inclusion in the study. All patients included were diagnosed with MG within the last 
two years before they were included in the study, but exact age at time of diagnosis or of 
symptom debut was not obtained. Hence it is possible that a patient diagnosed at age of 49 
is categorized as a late onset patient if the inclusion in the study occurred approximately 
two years later. However, only three patients were included in the study when aged 
between 50 and 52 years. A comparison between the groups after excluding these three 
patients yielded no significant change with regard to anti-Hsp70 antibody levels (p=0.787) 
and MMP9 (p=0.665). For MMP2 and MMP3 a significant difference in concentrations 
between EOMG and LOMG patients is dependent on whether these three patients are 
categorized as early or late onset. Because of this uncertainty, we found that this result 
could not be presented as a conclusive finding. 
MG patients were found to have increased levels of MMP2, MMP9 and anti-Hsp70 
antibodies compared to healthy controls. We measured the concentrations only once in 
each patient. This limits the conclusions that can be drawn. It is not possible to conclude 
whether these parameters are correlated to disease severity, as we could not monitor the 
serum levels during the fluctuations of the disease. Clinical grading of patients’ symptoms 
was not obtained. Levels of MMPs and anti-Hsp70 antibodies are found increased in other 
diseases, including, but not restricted to, autoimmune diseases [185-189]. This indicates 
that they are not disease specific, but their increase in several diseases affecting various 
organ systems suggests a role in the pathogenesis. The increased serum markers may well 
be due to local tissue destruction with local upregulation of MMPs and increased exposure 
to Hsp70 with subsequent antibody production. As many of the MMPs are important in 
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facilitating cell migration, any situation requiring the recruitment of certain cell types should 
in theory cause increased MMP-levels.  
The MMP levels measured did not take into account the enzymatic activity of these 
proteins, just their concentration. The MMPs have wide substrate specificity and thus 
requires potent regulatory mechanisms. Measuring the TIMP-levels in patient sera as well as 
the MMP concentrations would give a more comprehensive picture and possibly have 
impact on the conclusions drawn. A different approach to enzymatic activity for a functional 
assessment is zymography. This method uses many of the same principles as sodium 
dodecyl sulfate polyacrylamide gel electrophoresis, also known as SDS-PAGE. The two 
techniques differ in that the samples are not boiled or denatured beyond the addition of 
SDS, the gel used includes enzyme substrate, and following electrophoresis, the gels are 
incubated in appropriate buffer to allow the enzymes to degrade the substrate. After 
incubation, the gels are stained, and areas of enzymatic digestion will appear [190]. The 
relationship between MMP2 and -9 serum concentrations assessed by ELISA and enzyme 
activity by gelatin zymography, showed that the increased serum levels of the proteins in 
patients with SLE, RA and type-1 diabetes mellitus corresponded with increased enzymatic 
activity [151, 191]. It is therefore likely that the increased MMP serum levels presented in 
paper IV reflect increased enzymatic activity.  
As to which mechanisms MMPs may interfere with to contribute to the pathogenesis of MG, 
the lack of data makes this a speculation. But some indirect evidence exists. Zamecnik et al. 
reported in 2007 that 18 of 179 MG patients had lymphocytic infiltrations in muscle by CD8+ 
T cells. All MG patients with such infiltrations had lymphocyte-rich thymomas [192]. A 
previous study which included 30 MG patients, also found lymphocytic infiltrations in 
skeletal muscle, but concluded that the observations were more likely to reflect disturbed 
immune regulation in MG, than having of causal role in the disease [193]. The capacity of 
MMPs to promote immune cell migration has been shown in several in vivo studies [194-
196], and they are likely to be involved for the lymphocytes to extravasate into the muscle.  
Of the 129 MG patients included for MMP-measurements, 19 had concentrations exceeding 
the highest occurring healthy controls. The whole patient group did not differ from the 
control group with respect to MMP3, contrary to what has been shown in a previous study 
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[197]. The diverging results may be due to the inclusion of patients with predominantly 
periocular symptoms in paper IV. Any generalized symptoms tended to be mild. The role of 
MMP3 in development and maintenance of the NMJ has been reviewed by Werle in 2008 
[198]. Agrin is a known substrate for MMP3, and is essential for the formation of the NMJ. 
MMP3 null mice have increased postsynaptic AChR areas and postsynaptic membrane folds, 
and agrin, AChR and junctional folds are commonly seen in absence of a nerve terminal. It 
thus seems that the mutant mice without MMP3 lack the ability to remove unneeded agrin. 
MMP3 activity in the NMJ decreases with impaired synaptic transmission; whereas 
immunostaining shows that MMP3 is still present, suggesting the action of an inhibitor. 
Although the evidence seems compelling, transferring these animal- and in vitro studies to 
humans has to be done with caution. One hypothesis for the action of MMP3 in MG is 
involvement in remodeling of the NMJ following the complement mediated attack after 
antibodies bind to the AChRs. An increase in MMP3 levels and activity could cause an 
excessive breakdown of agrin resulting in an incomplete rebuild of the NMJ, as seen in MG 
[9]. The theory has its weakness in that a decrement in synaptic activity, as seen in MG, 
should, according to studies from animals [199], give reduced MMP3 activity and 
subsequently increased local agrin levels.   
Increased circulating levels of antibodies towards Hsp70 in MG and GBS patients suggest 
either current or previous exposure to the antigen. Hsp70 can act both as a peptide 
chaperone and as a maturation signal for dendritic cells (DC) [200]. Production of 
intracellular Hsp70 as well as Hsp70 release to the extracellular space increase in stressful 
conditions [119]. Skeletal muscle cells upregulate Hsp70 transcription and translation upon 
depolarization [201], ischemia [202], heat stress [203], and energy and milieu challenges 
[204]. Disturbances in Hsp70 function and signaling by increased levels of antibodies 
targeting the protein may reduce the muscle cell’s ability to cope with cellular stress and 
alter the immune response. In the development of MG, the NMJ is destroyed by antibody 
cross binding, complement activation and formation of membrane attack complexes [9]. 
The muscle cells would most likely respond to this stressor by up-regulating Hsp70 
production, and the released Hsp70 can then act as a stimulatory signal to the immune 
system through CD14, CD40, CD91 and members of the Toll like receptor family on antigen 
presenting cells and T-cells [123]. Immature DC treated with Hsp70 upregulate expression of 
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co-stimulatory molecules, and show increased capacity to activate peptide-specific T-cells 
[205]. In vivo experiments have demonstrated Hsp70’s importance in initiating an immune 
response to a self-antigen, switching from tolerance to autoimmune reactivity [136]. The 
biologic significance of anti-Hsp70 antibodies blocking Hsp70 function has been 
demonstrated in vivo when the antibodies prevented development of allergic contact 
hypersensitivity [130]. Our patient group consisted of MG patients with symptoms mostly 
limited to the ocular and periocular muscles, and their disease phenotype could therefore 
be described as mild compared to the severe generalized symptoms experienced by most 
MG patients. Based on the articles describing the immunological properties of Hsp70 and 
our current results, one can picture a scenario where inhibited Hsp70 signaling by antibody 
binding leads to reduced DC activation causing decreased activation of lymphocytes. This 
would slow down disease progression and, might explain the mild generalized symptoms 
among the group of MG patients that we have studied and the low frequency of anti-AChR 
positive patients. This theory remains speculative, as we do not have scientific data to 
support the specific role of Hsp70 in MG pathogenesis.  
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METHODOLOGICAL CONSIDERATIONS 
Cell culture and choice of cell types (papers I and II) 
Human myoblasts were acquired using a slightly modified protocol derived from Thompson 
et al. [206]. The skeletal muscle biopsy was manually minced under sterile conditions, after 
which it was dissociated by treatment with trypsin, type IV collagenase, and bovine serum 
albumin (BSA). The heterogenous cell suspension, containing both fibroblasts and muscle 
cells, was seeded into an uncoated cell culture flask and incubated for 1 hour. The 
fibroblasts adhered to the surface, whereas the myoblasts would remain in the cell 
suspension and were subcultured on gelatin coated surfaces for up to 10 passages. 
Homogeneity of the cell culture was ensured based on the morphological and behavioral 
properties of the cells, and fluorescent labeling of the cells using a titin-antibody.  
The cells started to differentiate upon reaching a high degree of confluency and when fetal 
calf serum was removed from the growth media and replaced with a low concentration (2%) 
of horse serum. Multinucleated myotubes would appear in the culture after 3 days.  
During normal muscle development, the myotubes need signals from the nerve terminals to 
form the punctuate expression of AChRs on the muscle cell membrane.  The AChR 
expression in humans is concentrated in the neuromuscular synapses and can reach a 
density of 10 000 to 20 000 receptors per μm2, whereas the remaining sarcolemma bears 
<10 per μm2. Agrin is released from the nerve terminals, and signals through MuSK to create 
clusters of AChRs linked together by rapsyn [207]. It may also serve as a synapse 
maintenance protein [208]. We differentiated the muscle cells with media not 
supplemented with Agrin, and hence the AChR expression in our cells did not resemble the 
in vivo expression pattern. The high concentration of AChRs in the NMJ makes cross binding 
of antibodies and complement activation more likely to occur. Such cross binding is central 
in the pathogenesis of MG [9]. It is therefore possible that the patient sera tested in paper I 
would have been more cytotoxic to the cells, if the differentiation process had been 
performed with Agrin stimulation of the culture. Our aim was to identify non-AChR antibody 
mechanisms. However, even such mechanisms may depend on AChR antibody binding and 
cross linking as a necessary first step.  
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Several other skeletal muscle cell systems exist, both primary cells and stable cell lines. We 
chose to prepare our own myoblast cell cultures, as the technique is relatively well 
established, although often with minor modifications [206, 209-211]. In addition to primary 
human cell lines, stable cell lines both from humans and other species are available, 
according to the European Collection of Cell Cultures, ECACC). These are often easier to 
obtain and culture, but aspects regarding phenotypic properties and inter-species reactions 
are of concern. Using skeletal myoblasts of human origin, any unspecific and unwanted 
reactions between factors in human sera and non-human cells was avoided.  
The same considerations were applied when choosing a cell line for the experiments 
performed in paper II. Initially the cell line HL-1 cardiomyocytes [212] was chosen. This cell 
line, however, was from mice and its use was discontinued as all human sera had a highly 
cytotoxic effect. We then decided to use the Girardi cell line, which has been used widely in 
heart studies including cell culture models [213-216]. It is a stable cell line of human origin, 
retains many of the properties of human myocardium. Potential inter-species reactions is 
therefore avoided.  
There have been reports published on contamination of the Girardi heart cell lines, even 
claiming that the cells actually were HeLa cells  [217]. ECCAC lists the cell type as being a 
HeLa derivative (cat. no. 93120822). Contamination of cell lines either by microorganisms or 
by a foreign cell line can happen without the handler’s knowledge and can have huge 
implications. Even though it was first described in the 1950s it remains a big problem [218]. 
Genetic profiling was not performed on the cells used in paper II, and thus we cannot be 
completely confident that the cells used in the experiments were what they were believed 
to be.  
The use of cell culture as a model system for studying human disease has its advantages and 
disadvantages. On the plus side, it is generally not very labor intensive and has a relatively 
low cost, compared to organ culture systems and animal models. On the down side, it 
differs from in vivo conditions in a variety of ways: Cell culture most often include only one 
or two cell types, the cells are often genetically modified making them have an infinite life 
span, the cells are cultured in medium without all the factors normally present in the human 
serum, and cultures have until the later years been confined to a two dimensional space. It 
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is important to be aware of these limitations in order not to over interpret the results 
gathered from the experiments. In an in vivo setting, any modifications to the wild type 
genome or any treatments or noxious stimuli applied are likely to be counter weighted by 
other parts of the animal (or human), yielding a milder response than what would be 
expected if the stimuli had been applied to only one cell type grown in cell culture. 
Serum samples from patients and controls (papers I-IV) 
The serum samples used in all experiments were stored as 1-2 ml aliquots at -20°C. The 
stability of antibodies and other serum factors has been investigated by Jellum et al. [219] 
using serum samples stored in the Janus Serum Bank, Norway. They noted that many serum 
factors, antibodies in particular, are very stable in frozen serum samples stored at -25°C. 
Two-dimensional protein electrophoresis was repeatedly performed on serum samples 
stored up to ten years, and the protein pattern remained constant, with some minor 
changes, over the years. These observations indicate that the primary structure of the 
protein remains intact, but do not shed any light on the stability of tertiary protein structure 
or biological activity. 
Storage in an ultra freezer at -80°C or in liquid nitrogen at -196°C would probably further 
slow down the breakdown of serum components. This type of storage would provide “more 
correct” results when measuring serum components. However, this aspect can partly be 
compensated for by storing samples from all groups tested in a similar way. 
Healthy control sera were all from Norwegian blood donors. The blood donors are assumed 
healthy, since the regulations in Norway do not allow people with acute or chronic cardiac 
disease, lung disease, urinary tract infections (including sexually transmitted diseases), 
diseases in the central nervous system and gastrointestinal diseases to donate blood. This 
includes cancer and autoimmune conditions. The samples were randomly selected from all 
blood donors. Information regarding sex and age were not obtainable, but the sex 
distribution among Norwegian blood donors reflects the public in general (52.3% males and 
47.2% females), and most donors (76.8%) are aged 26-55 years [220]. 
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CONCLUSIONS 
 
1. Sera from MG patients have a cytotoxic effect on human myoblasts in culture and 
are capable of inducing morphological changes. Sera from patients undergoing MG 
crisis were the most potent, and the factors responsible for the changes observed 
had a molecular weight >100 kDa.  
 
2. MG sera showed no cytotoxic potential when applied to cultured heart muscle cells. 
 
3. MG patients with a predominance of periocular symptoms have increased levels of 
anti-Hsp70 antibodies, MMP2 and MMP9. No difference was found for MMP3 when 
comparing the entire MG group to controls, but a subgroup of MG patients had 
MMP3 concentrations exceeding the maximum concentration in the healthy 
controls.  
 
4. Anti-Hsp70, MMP2, MMP3 and MMP9 concentrations did not differ between anti-
AChR positive and negative patients or when comparing patients with purely ocular 
and ocular plus generalized symptoms.  
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ERRATA 
Paper II:  
 
The control-bar is average enzyme release from 4 healthy individuals relative to levels 
measured in growth medium (not stated specifically in paper II). Enzyme release from 
untreated cells in growth medium was set to 100%. 
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